Bevacizumab is approved for the treatment of a challenging brain tumor called glioma. However, most cases of glioma continue to grow despite this therapy. In this study, researchers want to find the highest dose of an investigational drug called TRC105 that can be given safely with bevacizumab in patients with recurrent glioma.
Bevacizumab works by inhibiting the development of the blood vessels that tumors need to grow and spread. TRC105 also targets tumor blood vessel development, and may help bevacizumab work better against glioma. Both drugs are given intravenously (by vein).